|Written||2013-05||Adriana Zamecnikova, Soad Al Bahar|
|Kuwait Cancer Control Center, Laboratory of Cancer Genetics, Department of Hematology, Shuwaikh, 70653, Kuwait|
|ICD-Topo||C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS|
|ICD-Morpho||9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS|
|ICD-Morpho||9975/3 Chronic myelogenous leukaemia, BCR-ABL1 positive; Myeloproliferative neoplasm, unclassifiable; Myelodysplastic/myeloproliferative neoplasm, unclassifiable|
|ICD-Morpho||9989/3 Myelodysplastic syndrome, unclassifiable|
|Clinics and Pathology|
|Disease||BCR-ABL-negative chronic myeloproliferative neoplasms (MPN): essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), myelodysplastic syndromes (MDS) and less frequently in acute myeloid leukemia and other myeloproliferative disorders.|
|Etiology||Although the underlying mechanism for these chromosomal alterations is unclear, it is possible that chromosomes with large constitutive heterochromatin bands such as chromosome 1 may be at risk of centromeric instability and be predisposed to centromeric fusion with other chromosomes. This possibility is supported by observations that unbalanced chromosome rearrangements frequently involve the fusion of the large constitutive heterochromatin regions of chromosomes. Therefore, it is likely, that larger constitutive heterochromatin chromosomes may be more at risk of centromeric instability and predisposed to chromosome breakage at the centromere (Caramazza et al., 2010; Millington et al., 2008).|
|Pathology||While the mechanism(s) is not entirely clear, hypomethylation of heterochromatic 1q sequences may be a cause of centromeric instability leading to centromeric DNA decondensation. Immunodeficiency may be a factor involved in centromeric instability, at least in some cases. This is supported by observations of high frequency of centromeric heterochromatin instability and frequent 1q exchanges in some patients with immunodeficiency (Sawyer et al., 1995a; Sawyer et al., 1995b; Polito et al., 1996).|
|Prognosis||While mechanistically unbalanced 1q abnormalities result in gain of 1q, the prognostic implication may be entirely different, depending on partner chromosomes. Although more case studies are needed, previously published data indicate a possible association of unbalanced 1q rearrangements with a highly proliferative phenotype in myeloproliferative disorders with a propensity of disease transformation.|
| der(Y)t(Y;1)(q11-12;12-25). Myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) (M2, M4 mostly), chronic myelomonocytic leukemia (CMMoL) and less frequently other chronic myeloproliferative disorders (MPD). Most cases involve Yq12 and 1q12 breakpoints. Sole anomaly in the majority of myeloid disorders, may be accompanied by numerical anomalies (+8, +9). Rarely found in lymphoid malignancies as part of complex karyotypes (Manabe et al., 2013; Michaux et al., 1996b). |
der(1)t(1;1)(p36;q11-q32). The balanced translocation t(1;1)(p36;q21) involving the DUSP10/PRDM16 genes is associated with myeloid disorders; the unbalanced der(1)t(1;1) involving 1q11-32 breakpoints may be observed in both myeloid and lymphoid proliferations and is frequently associated with a highly complex karyotype (Duhoux et al., 2011; Noguchi et al., 2007).
der(2)t(1;2)(q12;q37). Identified in patients suffering from different acute myeloid leukemia subtypes; less frequently chronic myeloid disorders. Found mostly in complex karyotypes; likely to be a secondary anomaly. The balanced t(1;2)(q12;q37) is occurring in acute myeloid leukemia (Busson-Le Coniat et al., 1999).
der(5)t(1;5)(q12-q25;q13-q35). Found in lymphoid and myeloid malignancies with cytogenetically heterogeneous breakpoints. In both lineages found as part of complex karyotypes, most likely as a secondary anomaly. In myeloid disorders the anomaly seems to confer a poor prognosis with a possible link to previous mutagenic exposure. The balanced t(1;5)(q23;q33) involving the PDGFRB gene is associated with a myeloproliferative disorder and eosinophilia (Johansson et al., 1997).
der(6)t(1;6)(q21-23;p21.3). Found in chronic myeloproliferative disorders and less frequently in AML/MDS. DNA sequences may be overrepresented at 6p as either cryptic duplications or cryptic low-copy gains. The presence of fragile site FRA6C, located in 6p22 suggest, that 6p gains may arise from acquired and/or congenital genomic instability. In addition, the occurrence of translocations involving 6p22 after chemotherapy or radiation therapy indicates, that one or more therapeutic agents might play a role in their origin (Dingli et al., 2005; Busson-Le Coniat et al., 1999).
der(1;7)(q10;p10). Defines a unique clinicopathological subgroup of myeloid neoplasms; found particularly in MDS and AML and less frequently in chronic myeloproliferative disorders. Previous history of chemo- and/or radiotherapies has been described in more than half cases. Sole cytogenetic anomaly in around one-half cases, limited number of additional abnormalities, consisting mostly of trisomy 8. The unbalanced translocation, der(1;7)(q10;p10), leading to allelic imbalance of trisomy 1q and 7q monosomy is associated with high rates of progression to AML in MDS and unfavorable prognosis (Caramazza et al., 2010; Slovak et al., 2009; Sanada et al., 2007).
der(1;9)(q10;p10). Rarely found in patients of essential thrombocythemia with JAK2 V617F mutation that transformed to acute myelogenous leukemia or to myelofibrosis, suggesting the anomaly may play a role in the progression of myeloproliferative neoplasms (Bobadilla et al., 2007).
der(9)t(1;9)(q11;q34). Rare occurrence, found in 3 cases of acute myeloid leukemia, 1 case of polycythemia vera, 1 case with chronic myelomonocytic leukemia and 1 case of multiple myeloma (Suh et al., 2009).
der(9)t(1;9)(q12;q12). Rare, found in 2 patients with polycythemia vera in transformation and in 1 patient with myelofibrosis, which later evolved into acute myelomonocytic leukemia; may be consistently associated with myeloproliferative disorders showing a high propensity to transformation. Sole abnormality in most cases; gain of 9p might play a role for gain of function of the JAK2 gene on 9p24 (Rege-Cambrin et al., 1991).
der(1;10)(q10;p10). Rare anomaly, described in patients with myelodysplastic syndromes (Leon et al., 2011).
der(11)t(1;11)(q12-21;q14-25). Unbalanced form is identified in myeloid and lymphoid malignancies; described mainly in secondary cases as part of highly complex karyotypes (Secker-Walker et al., 1998; Douet-Guilbert et al., 2008). The balanced t(1;11)(q21;q23) and MLL rearrangement is associated with in AML, mainly M4/M5.
der(12)t(1;12)(q11-21;p11-13). Rare abnormality, found in myeloid and lymphoid neoplasm, described in complex karyotypes; most likely as a secondary rearrangement (La Starza et al., 1999; Andersen et al., 2005).
der(1;13)(q10;q10). Uncommon in myeloid malignancies; described in chronic myeloid neoplasms including polycythemia vera and essential thrombocythemia (Flach et al., 2011; Tanaka et al., 2006).
der(1;14)(q10;q10). Detected in chronic and acute myeloid disorders found as a single anomaly in a majority of patients (Fogu et al., 2012).
dic(1;15)(p11;p11). Found in patients with various conditions, including both lymphoid and myeloid neoplasms. Rare, but nonrandom anomaly in MPD, mostly MDS and AML (Michaux et al., 1996a).
der(16)t(1;16)(q11-25;q11-24). Occurs in a wide variation of hematologic malignancies mostly as a part of complex karyotypes; limited number of additional anomalies in myeloproliferative disorders. A rare but nonrandom abnormality in myelodysplastic syndromes, associated with male predominance, suggesting a putative association of this translocation with male gender (Lunghi et al., 2010).
der(18)t(1;18)(q10-25;q11-23). Heterogeneous breakpoints; the anomaly is relatively restricted to myeloid disorders; found mostly in a highly proliferative ET/PV phenotype with a propensity to transform into myelofibrosis and acute leukemia. In particular, the subtype der(18)(q10;q10) seems to be associated with the aggressive phenotype of PV. Found as the sole karyotypic abnormality in the majority of patients. A relatively high incidence of JAK2 mutations in these patients suggests a possible link between JAK2 mutations and disease etiology (Trautmann et al., 1992; Diez-Martin et al., 1991; Gangat et al., 2008; Wan et al., 2001a; Azuma et al., 2010; Alter et al., 2000).
der(1)t(1;19)(q23;p13.1). Cytogenetic appearance identical to t(1;19)(q23;p13.3), a specific aberration in ALL; occasionally described in myeloid neoplasms (MDS and AML) with various 1q21-1q25 breakpoints (Tchinda et al., 2002).
der(20)t(1;20)(q10-21;q11-13). Rare occurrence in myeloid lineages; apparently secondary anomaly, found mostly as part of complex karyotypes (Wan et al 2001b; Raimondi et al., 1999).
|Cytogenetics Morphological|| Unbalanced rearrangements, resulting in partial or total trisomy of 1q and loss of genomic sequences from the partner chromosome.|
Abnormal clones containing extra copies of 1q may originate by several mechanisms, including whole-arm translocations, unbalanced rearrangements between variable partner chromosomes, 'dicentric' translocations and partial duplications of 1q.
|Additional anomalies||Usually appear as a sole chromosomal abnormality during the entire clinical courses or accompanied only by a limited number of additional abnormalities, suggesting that gain of 1q plays a role in the pathogenesis of these rearrangements.|
|Genes involved and Proteins|
|Note||No specific gene targets at the breakpoints are likely to be involved. In these rearrangements, the critical region between 1q21 and 1q32 is known to be commonly spanned, but no pathogenetically relevant genes have been demonstrated.|
|Result of the chromosomal anomaly|
|Oncogenesis||The unbalanced nature of these rearrangements indicates that mechanistically, either trisomy of 1q and/or loss of putative tumor suppressors may potentially contribute to disease pathogenesis. As the gain of 1q that results from these translocations is consistently associated with myeloproliferative disorders, it is likely that certain chromosome 1q regions are pathogenetically relevant to both chronic and advanced phases of MPN. This finding suggests that the gain of 1q and appears to be one of the progressional steps in these disorders, while the loss of tumor suppressor genes may also contribute to clonal proliferation, analogous to numerical aberrations and chromosome deletions.|
|To be noted|
|A relatively high incidence of JAK2 mutations in combination with 1q rearrangements in MPN, suggests a possible link between JAK2 mutations and 1q rearrangements in myeloid malignances, pathologically relevant either at diagnosis or in advanced stages of the disease.|
|Fanconi anemia: myelodysplasia as a predictor of outcome.|
|Alter BP, Caruso JP, Drachtman RA, Uchida T, Velagaleti GV, Elghetany MT.|
|Cancer Genet Cytogenet. 2000 Mar;117(2):125-31.|
|Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study.|
|Andersen MK, Christiansen DH, Pedersen-Bjergaard J.|
|Genes Chromosomes Cancer. 2005 Apr;42(4):358-71.|
|Derivative (1;18)(q10;q10) in essential thrombocythemia.|
|Azuma T, Yamanouchi J, Inoue K, Kohno M, Narumi H, Fujiwara H, Yakushijin Y, Hato T, Yasukawa M.|
|Cancer Genet Cytogenet. 2010 May;199(1):62-4. doi: 10.1016/j.cancergencyto.2010.02.001.|
|An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.|
|Bobadilla D, Enriquez EL, Alvarez G, Gaytan P, Smith D, Slovak ML.|
|Br J Haematol. 2007 Mar;136(6):806-13.|
|Fluorescence in situ hybridization analysis of chromosome 1 abnormalities in hematopoietic disorders: rearrangements of DNA satellite II and new recurrent translocations.|
|Busson-Le Coniat M, Salomon-Nguyen F, Dastugue N, Maarek O, Lafage-Pochitaloff M, Mozziconacci MJ, Baranger L, Brizard F, Radford I, Jeanpierre M, Bernard OA, Berger R.|
|Leukemia. 1999 Dec;13(12):1975-81.|
|Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.|
|Caramazza D, Hussein K, Siragusa S, Pardanani A, Knudson RA, Ketterling RP, Tefferi A.|
|Eur J Haematol. 2010 Mar;84(3):191-200. doi: 10.1111/j.1600-0609.2009.01392.x. Epub 2009 Nov 30. (REVIEW)|
|Chromosome studies in 104 patients with polycythemia vera.|
|Diez-Martin JL, Graham DL, Petitt RM, Dewald GW.|
|Mayo Clin Proc. 1991 Mar;66(3):287-99.|
|Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.|
|Dingli D, Grand FH, Mahaffey V, Spurbeck J, Ross FM, Watmore AE, Reilly JT, Cross NC, Dewald GW, Tefferi A.|
|Br J Haematol. 2005 Jul;130(2):229-32.|
|Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.|
|Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C, De Braekeleer M.|
|Ann Hematol. 2008 Jul;87(7):537-44. doi: 10.1007/s00277-008-0462-3. Epub 2008 Mar 19.|
|Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies.|
|Duhoux FP, Ameye G, Lambot V, Herens C, Lambert F, Raynaud S, Wlodarska I, Michaux L, Roche-Lestienne C, Labis E, Taviaux S, Chapiro E, Nguyen-Khac F, Struski S, Dobbelstein S, Dastugue N, Lippert E, Speleman F, Van Roy N, De Weer A, Rack K, Talmant P, Richebourg S, Mugneret F, Tigaud I, Mozziconacci MJ, Laibe S, Nadal N, Terre C, Libouton JM, Decottignies A, Vikkula M, Poirel HA; Groupe Francophone de Cytogenetique Hematologique (GFCH); Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO).|
|PLoS One. 2011;6(10):e26311. doi: 10.1371/journal.pone.0026311. Epub 2011 Oct 21.|
|An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling.|
|Flach J, Dicker F, Schnittger S, Schindela S, Kohlmann A, Haferlach T, Kern W, Haferlach C.|
|Leukemia. 2011 Apr;25(4):713-8. doi: 10.1038/leu.2010.304. Epub 2011 Jan 14.|
|Unbalanced 1q whole-arm translocation resulting in der(14)t(1;14)(q11-12;p11) in myelodysplastic syndrome.|
|Fogu G, Campus PM, Cambosu F, Moro MA, Sanna R, Fozza C, Nieddu RM, Longinotti M, Montella A.|
|Cytogenet Genome Res. 2012;136(4):256-63. doi: 10.1159/000338437. Epub 2012 May 10. (REVIEW)|
|Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.|
|Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A, Li CY, Ketterling RP, Tefferi A.|
|Eur J Haematol. 2008 Mar;80(3):197-200. Epub 2007 Dec 7.|
|Conventional cytogenetics in myelofibrosis: literature review and discussion.|
|Hussein K, Van Dyke DL, Tefferi A.|
|Eur J Haematol. 2009 May;82(5):329-38. doi: 10.1111/j.1600-0609.2009.01224.x. Epub 2009 Jan 9. (REVIEW)|
|Translocations between the long arms of chromosomes 1 and 5 in hematologic malignancies are strongly associated with neoplasms of the myeloid lineages.|
|Johansson B, Brondum-Nielsen K, Billstrom R, Schiodt I, Mitelman F.|
|Cancer Genet Cytogenet. 1997 Dec;99(2):97-101.|
|Characterization of 12p molecular events outside ETV6 in complex karyotypes of acute myeloid malignancies.|
|La Starza R, Stella M, Testoni N, Di Bona E, Ciolli S, Marynen P, Martelli MF, Mandelli F, Mecucci C.|
|Br J Haematol. 1999 Nov;107(2):340-6.|
|Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.|
|Leon A, Staropoli JF, Hernandez JM, Longtine JA, Kuo FC, Dal Cin P.|
|Leuk Res. 2011 Sep;35(9):1188-92. doi: 10.1016/j.leukres.2011.02.001. Epub 2011 Mar 3.|
|Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature.|
|Lunghi M, Casorzo L, De Paoli L, Riccomagno P, Rossi D, Gaidano G.|
|Cancer Genet Cytogenet. 2010 Jan 1;196(1):89-92. doi: 10.1016/j.cancergencyto.2009.07.003. (REVIEW)|
|A rare der(Y)t(Y;1)(q12;q12) in a patient with post-polycythemic myelofibrosis: a case report.|
|Manabe M, Takeda O, Okita J, Takakuwa T, Harada N, Nakano H, Okamoto S, Aoyama Y, Kumura T, Ohta T, Furukawa Y, Mugitani A.|
|Am J Blood Res. 2013 May 5;3(2):186-90. Print 2013.|
|Dicentric (1;15) in myeloid disorders.|
|Michaux L, Dierlamm J, Mecucci C, Meeus P, Ameye G, Libouton JM, Verhoef G, Ferrant A, Louwagie A, Verellen-Dumoulin C, Van Den Berghe H.|
|Cancer Genet Cytogenet. 1996a May;88(1):86-9. (REVIEW)|
|Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature.|
|Michaux L, Wlodarska I, Vellosa ER, Verhoef G, Van Orshoven A, Michaux JL, Scheiff JM, Mecucci C, Van den Berghe H.|
|Cancer Genet Cytogenet. 1996b Jan;86(1):35-8. (REVIEW)|
|Role of chromosome 1 pericentric heterochromatin (1q) in pathogenesis of myelodysplastic syndromes: report of 2 new cases.|
|Millington K, Hudnall SD, Northup J, Panova N, Velagaleti G.|
|Exp Mol Pathol. 2008 Apr;84(2):189-93. doi: 10.1016/j.yexmp.2007.10.003. Epub 2007 Oct 23.|
|Dual-specificity phosphatase 10 is fused to MDS1/EVI1-like gene 1 in a case of acute myelogenous leukemia with der1t1;1(p36.3;q21).|
|Noguchi M, Tashiro H, Shirasaki R, Gotoh M, Kawasugi K, Shirafuji N.|
|Int J Hematol. 2007 Feb;85(2):175-6.|
|Centromeric instability of chromosome 1 resulting in multibranched chromosomes, telomeric fusions, and "jumping translocations" of 1q in a human immunodeficiency virus-related non-Hodgkin's lymphoma.|
|Polito P, Canzonieri V, Cilia AM, Gloghini A, Carbone A, Gaidano G.|
|Cancer. 1996 Sep 1;78(5):1142-4.|
|Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821.|
|Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, Weinstein HJ, Carroll AJ.|
|Blood. 1999 Dec 1;94(11):3707-16.|
|Extra translocation +der(1q9p) is a prognostic indicator in myeloproliferative disorders.|
|Rege-Cambrin G, Speleman F, Kerim S, Scaravaglio P, Carozzi F, Dal Cin P, Michaux JL, Offner F, Saglio G, Van den Berghe H.|
|Leukemia. 1991 Dec;5(12):1059-63. (REVIEW)|
|Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms.|
|Sanada M, Uike N, Ohyashiki K, Ozawa K, Lili W, Hangaishi A, Kanda Y, Chiba S, Kurokawa M, Omine M, Mitani K, Ogawa S.|
|Leukemia. 2007 May;21(5):992-7. Epub 2007 Feb 22.|
|Chromosome instability in ICF syndrome: formation of micronuclei from multibranched chromosomes 1 demonstrated by fluorescence in situ hybridization.|
|Sawyer JR, Swanson CM, Wheeler G, Cunniff C.|
|Am J Med Genet. 1995b Mar 27;56(2):203-9.|
|Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop.|
|Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB.|
|Leukemia. 1998 May;12(5):840-4.|
|Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.|
|Slovak ML, O'Donnell M, Smith DD, Gaal K.|
|Cancer Genet Cytogenet. 2009 Sep;193(2):78-85. doi: 10.1016/j.cancergencyto.2009.04.013.|
|Chronic myelomonocytic leukemia with der(9)t(1;9)(q11;q34) as a sole abnormality.|
|Suh B, Park TS, Kim JS, Song J, Kim J, Yoo JH, Choi JR.|
|Ann Clin Lab Sci. 2009 Summer;39(3):307-12. (REVIEW)|
|Multiple granulocytic sarcomas in essential thrombocythemia.|
|Tanaka Y, Nagai Y, Mori M, Fujita H, Togami K, Kurata M, Matsushita A, Maeda A, Nagai K, Tanaka K, Takahashi T.|
|Int J Hematol. 2006 Dec;84(5):413-6.|
|Novel der(1)t(1;19) in two patients with myeloid neoplasias.|
|Tchinda J, Volpert S, Neumann T, Kennerknecht I, Ritter J, Buchner T, Berdel WE, Horst J.|
|Cancer Genet Cytogenet. 2002 Feb;133(1):61-5.|
|Multiple chromosomal changes and karyotypic evolution in a patient with myelofibrosis.|
|Trautmann U, Rubbert A, Gramatzki M, Henschke F, Gebhart E.|
|Cancer Genet Cytogenet. 1992 Jul 1;61(1):6-10.|
|Cytogenetic biclonality in polycythemia vera: unusual and unrelated clones.|
|Wan TS, Ma SK, Ho MY, Chan LC, Yip SF, Wong LG, Yeung YM.|
|Cancer Genet Cytogenet. 2001b Nov;131(1):86-9.|
|This paper should be referenced as such :|
|Zamecnikova, A ; Al, Bahar S|
|1q translocations (unbalanced) in myeloid malignancies|
|Atlas Genet Cytogenet Oncol Haematol. 2013;17(12):845-848.|
|Free journal version : [ pdf ] [ DOI ]|
|On line version : http://AtlasGeneticsOncology.org/Anomalies/Unb1qMyeloidMalignID1638.html|
|arrayMap (UZH-SIB Zurich)||Topo ( C42) Morph ( 9861/3) - [auto + random 100 samples .. if exist ] [tabulated segments]|
|arrayMap (UZH-SIB Zurich)||Topo ( C42) Morph ( 9975/3) - [auto + random 100 samples .. if exist ] [tabulated segments]|
|arrayMap (UZH-SIB Zurich)||Topo ( C42) Morph ( 9989/3) - [auto + random 100 samples .. if exist ] [tabulated segments]|
|REVIEW articles||automatic search in PubMed|
|Last year articles||automatic search in PubMed|
|All articles||automatic search in PubMed|
|© Atlas of Genetics and Cytogenetics in Oncology and Haematology||indexed on : Wed Nov 28 16:24:46 CET 2018|
For comments and suggestions or contributions, please contact us